Alternative complement pathway activation during invasive coronary procedures in acute myocardial infarction and stable angina pectoris.

[1]  T. Funahashi,et al.  High serum C1q-binding adiponectin levels in male patients with acute coronary syndrome , 2014, Cardiovascular Diabetology.

[2]  M. Osthoff,et al.  Impact of Mannose-Binding Lectin Deficiency on Radiocontrast-Induced Renal Dysfunction , 2013, BioMed research international.

[3]  I. Préda,et al.  Elevated C1rC1sC1inh levels independently predict atherosclerotic coronary heart disease. , 2013, Molecular immunology.

[4]  S. Pedersen,et al.  Soluble form of membrane attack complex independently predicts mortality and cardiovascular events in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. , 2012, American heart journal.

[5]  Fred S Apple,et al.  Third universal definition of myocardial infarction , 2012 .

[6]  Erdmann Seeliger,et al.  Contrast-induced kidney injury: mechanisms, risk factors, and prevention. , 2012, European heart journal.

[7]  P. Armstrong,et al.  Pexelizumab fails to inhibit assembly of the terminal complement complex in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Insight from a substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. , 2012, American heart journal.

[8]  S. Thiel,et al.  Complement Activation and Prognosis in Patients With Type 2 Diabetes and Myocardial Infarction , 2012, Diabetes Care.

[9]  Raimund Erbel,et al.  [2011 ESC guidelines on the diagnosis and treatment of peripheral artery diseases]. , 2012, Revue medicale de Liege.

[10]  C. Held,et al.  Association between adoption of evidence-based treatment and survival for patients with ST-elevation myocardial infarction. , 2011, JAMA.

[11]  Volkmar Falk,et al.  Guidelines on Myocardial Revascularization the Task Force on Myocardial Revascularization of the European Society of Cardiology (esc) and the European Association for Cardio-thoracic Surgery (eacts) Developed with the Special Contribution of the European Association for Percutaneous Cardiovascular I , 2022 .

[12]  J. Hartikainen,et al.  Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries , 2009, European heart journal.

[13]  M. Alpert,et al.  Effect of radiographic contrast media on markers of complement activation and apoptosis in patients with chronic coronary artery disease undergoing coronary angiography. , 2009, The Journal of invasive cardiology.

[14]  O. Wagner,et al.  Local complement activation triggers neutrophil recruitment to the site of thrombus formation in acute myocardial infarction , 2009, Thrombosis and Haemostasis.

[15]  Sonia Youhanna,et al.  Comparison of the systemic levels of inflammatory markers after percutaneous coronary intervention with bare metal versus sirolimus-eluting stents. , 2009, Journal of interventional cardiology.

[16]  G. Biondi-Zoccai,et al.  Pexelizumab in ischemic heart disease: a systematic review and meta-analysis on 15,196 patients. , 2008, The Journal of thoracic and cardiovascular surgery.

[17]  L. Entz,et al.  Early complement activation follows eversion carotid endarterectomy and correlates with the time of clamping of the carotid artery. , 2008, Molecular immunology.

[18]  W. Gray,et al.  Endovascular therapies for peripheral arterial disease: an evidence-based review. , 2007, Circulation.

[19]  O. Wiklund,et al.  Dissociation of the Inflammatory Reaction following PCI for Acute Myocardial Infarction. , 2007, The Journal of invasive cardiology.

[20]  S. Meri,et al.  Function and regulation of the complement system in cardiovascular diseases. , 2007, Frontiers in bioscience : a journal and virtual library.

[21]  T. Woodruff,et al.  Complement mediators in ischemia-reperfusion injury. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[22]  C. Becker,et al.  Pathophysiology of contrast-induced nephropathy. , 2006, The American journal of cardiology.

[23]  V. Hasselblad,et al.  Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: a systematic overview. , 2006, American heart journal.

[24]  T. Omland,et al.  Inflammatory response and re-stenosis after percutaneous coronary intervention in heart transplant recipients and patients with native atherosclerosis. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[25]  N. Toprak,et al.  Complement activation in acute coronary syndromes , 2005, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[26]  C. Stefanadis,et al.  Inflammation and restenosis after percutaneous coronary interventions. , 2004, European heart journal.

[27]  P. Kovanen,et al.  Role of complement activation in atherosclerosis , 2003, Current opinion in lipidology.

[28]  H. Dauerman,et al.  Increase in Interleukin-6 in the First Hour after Coronary Stenting: An Early Marker of the Inflammatory Response , 2003, Journal of Thrombosis and Thrombolysis.

[29]  A. Keren,et al.  Increased C-reactive protein level after coronary stent implantation in patients with stable coronary artery disease. , 2003, American heart journal.

[30]  M. Walport,et al.  Complement. Second of two parts. , 2001, The New England journal of medicine.

[31]  M. Walport.  Complement. First of two parts. , 2001, The New England journal of medicine.

[32]  S. Meri,et al.  Complement activation after oxidative stress: role of the lectin complement pathway. , 2000, The American journal of pathology.

[33]  G. Stone,et al.  Long-term clinical events following creatine kinase--myocardial band isoenzyme elevation after successful coronary stenting. , 2000, Journal of the American College of Cardiology.

[34]  Wiklund Ra,et al.  First of two parts , 1997 .

[35]  J. Kowalski,et al.  Complement activates neutrophils during PTCA procedure in patients with unstable angina pectoris. , 1997, International journal of cardiology.

[36]  E. Topol,et al.  Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. , 1996, Circulation.

[37]  E. Topol,et al.  Defining the appropriate threshold of creatine kinase elevation after percutaneous coronary interventions. , 1996, American heart journal.

[38]  D. Baim,et al.  Elevation of the creatine kinase myocardial isoform following otherwise successful directional coronary atherectomy and stenting. , 1994, The American journal of cardiology.

[39]  Mosteller Rd.  Simplified Calculation of Body-Surface Area , 1987 .

[40]  W. Hollander,et al.  Soluble proteins in the human atheroschlerotic plaque , 1979 .

[41]  P. Garred,et al.  The Lectin Pathway of Complement and Biocompatibility. , 2015, Advances in experimental medicine and biology.

[42]  D. McManus,et al.  Recent trends in the incidence, treatment, and outcomes of patients with STEMI and NSTEMI. , 2011, The American journal of medicine.

[43]  T. Ueland,et al.  Inflammatory response to percutaneous coronary intervention in stable coronary artery disease , 2010, Journal of Thrombosis and Thrombolysis.

[44]  G. Maurer,et al.  Coronary late lumen loss of drug eluting stents is associated with increased serum levels of the complement components C3a and C5a. , 2010, Atherosclerosis.

[45]  M. Saletti,et al.  Changes of some immune functions after percutaneous transluminal coronary angioplasty (PTCA). , 1995, International journal of clinical pharmacology research.

[46]  S. Rendig,et al.  Limitation of reperfusion injury by a monoclonal antibody to C5a during myocardial infarction in pigs. , 1995, The American journal of physiology.

[47]  I. Toda,et al.  The complement system in ischemic heart disease. , 1990, Circulation.